EC Number   |
Title |
Organism |
|---|
   3.4.21.B10 | A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy |
Mus musculus |
| 3.4.21.B10 | A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering |
Homo sapiens |
| 3.4.21.B10 | Activity of human kallikrein-related peptidase 6 (KLK6) on substrates containing sequences of basic amino acids. Is it a processing protease? |
Homo sapiens |
| 3.4.21.B10 | Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids |
Mus musculus |
| 3.4.21.B10 | Kallikrein-related peptidase 6 exacerbates disease in an autoimmune model of multiple sclerosis |
Mus musculus |
| 3.4.21.B10 | Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms |
Mus musculus |
| 3.4.21.B10 | Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients |
Homo sapiens |
| 3.4.21.B10 | KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species |
Homo sapiens |
| 3.4.21.B10 | Study of kallikrein-related peptidase 6 (KLK6) and its complex with alpha1-antitrypsin in biological fluids |
Homo sapiens |
| 3.4.21.B10 | The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins |
Homo sapiens |
